Immunotherapy for Glioblastomas
Glioblastoma (GBM), a WHO grade IV brain tumor, is an aggressive tumor with poor prognosis; even with current standard care of triple therapy, consisting of surgical resection, chemo and radiation therapy, the patients' median survival time is only approximately 15 months. Recent practice shows...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Ebooks |
| Published: |
IntechOpen,
2020-04-02.
|
| Subjects: | |
| Online Access: | Get Online |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 01349 am a22002413u 4500 | ||
|---|---|---|---|
| 001 | intechopen_books_8339 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Hu, Wan-Ming |e author |
| 700 | 1 | 0 | |a Shan, Frank Y. |e author |
| 700 | 1 | 0 | |a Mukherjee, Sanjib |e author |
| 700 | 1 | 0 | |a Levacic, Danijela |e author |
| 700 | 1 | 0 | |a Huang, Jason H. |e author |
| 245 | 0 | 0 | |a Immunotherapy for Glioblastomas |
| 260 | |b IntechOpen, |c 2020-04-02. | ||
| 500 | |a https://mts.intechopen.com/articles/show/title/immunotherapy-for-glioblastomas | ||
| 520 | |a Glioblastoma (GBM), a WHO grade IV brain tumor, is an aggressive tumor with poor prognosis; even with current standard care of triple therapy, consisting of surgical resection, chemo and radiation therapy, the patients' median survival time is only approximately 15 months. Recent practice shows that immunotherapy made some progress in some other solid tumors, like melanoma or non-small cell lung cancer. This chapter is going to review some advances in immunotherapy for GBM. | ||
| 540 | |a https://creativecommons.org/licenses/by/3.0/ | ||
| 546 | |a en | ||
| 690 | |a Neurosurgical Procedures - Innovative Approaches | ||
| 655 | 7 | |a Chapter, Part Of Book |2 local | |
| 786 | 0 | |n https://www.intechopen.com/books/8339 | |
| 787 | 0 | |n ISBN:978-1-78985-927-0 | |
| 856 | \ | \ | |u https://mts.intechopen.com/articles/show/title/immunotherapy-for-glioblastomas |z Get Online |